Clinical Trial Update: Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB) (NC-002) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating an 8-week regimen of moxifloxacin, pretomanid (PA-824), and pyrazinamide for drug-sensitive and multidrug-resistant pulmonary tuberculo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Tuberculosis

Drugs mentioned

• Moxifloxacin (moxifloxacin)
• PA-824 (pretomanid)
• Pyrazinamide (pyrazinamide)

Snippet

Sponsor: Global Alliance for TB Drug Development | Conditions: Pulmonary Tuberculosis | Phase 2 | Status: COMPLETED | Results posted: 2016-12-12